Antiviral stockpiles for influenza pandemics from the household perspective: Treatment alone versus treatment with prophylaxis

被引:1
|
作者
Kwok, Kin On [1 ,2 ]
Leung, Gabriel M. [1 ,2 ]
Mak, Peter [1 ,2 ]
Riley, Steven [1 ,2 ,3 ]
机构
[1] Univ Hong Kong, Dept Community Med, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China
[3] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, Sch Publ Hlth, London SW7 2AZ, England
基金
英国惠康基金; 美国国家卫生研究院;
关键词
Pandemic influenza (pandemic flu); Treatment; Prophylaxis; Antiviral drugs; Mathematical models; UNITED-STATES; A H1N1; VIRUS; TRANSMISSION; STRATEGIES; OUTBREAK;
D O I
10.1016/j.epidem.2012.11.001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Model-based studies of antiviral use to mitigate the impact of moderate and severe influenza pandemics implicitly take the viewpoint of a central public health authority. However, it seems likely that the key decision of when to use antivirals will be made at the household level. We used a stochastic compartmental model of the transmission of influenza within and between households to evaluate the expected mortality under two strategies: households saving available antivirals for treatment only and households implementing prophylaxis as well as treatment. Given that every individual in the population was allocated a single course of antivirals, we investigated the impact of these two strategies for a wide range of AVE(D), the efficacy of antivirals in preventing death in severe cases (AVE(D) = 1 for complete protection). We found a cross-over point for our baseline parameter values in a regime where antivirals were still highly effective in reducing the chance of death: below AVE(D) = 0.9 the optimal strategy was for households to use both treatment and prophylaxis. We also considered the possibility that a small number of households might "cheat" by choosing to follow the treatment-only strategy when other households were following treatment with prophylaxis. The cross-over point for cheating households was considerably lower, at AVE(D) = 0.6, but substantially above 0. These results suggest that unless antivirals are almost completely effective in reducing the chance of death in serious cases, households will likely be better served implementing prophylaxis as well as treatment. More generally, our study illustrates the potential value of considering viewpoints other than a central authority when conducting model-based analysis of interventions against infectious disease. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:92 / 97
页数:6
相关论文
共 50 条
  • [31] RIMANTADINE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA-A
    HANNOUN, C
    REVUE DE MEDECINE INTERNE, 1988, 9 (05): : 554 - 558
  • [32] Oseltamivir for treatment and prophylaxis of influenza infection
    Schirmer, Patricia
    Holodniy, Mark
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (03) : 357 - 371
  • [33] The influenza virus in relation to prophylaxis and treatment
    不详
    LANCET, 1935, 2 : 27 - 27
  • [34] INFLUENZA - RECENT DEVELOPMENTS IN PROPHYLAXIS AND TREATMENT
    GALBRAITH, AW
    BRITISH MEDICAL BULLETIN, 1985, 41 (04) : 381 - 385
  • [35] Advances in the prophylaxis and treatment of influenza illness
    Hayden, FG
    AMERICAN JOURNAL OF MANAGED CARE, 2000, 6 (05): : S247 - S254
  • [36] Prophylaxis and treatment of influenza virus infection
    Kandel, R
    Hartshorn, KL
    BIODRUGS, 2001, 15 (05) : 303 - 323
  • [37] Prophylaxis and Treatment of Influenza Virus Infection
    Ruth Kandel
    Kevan L. Hartshorn
    BioDrugs, 2001, 15 : 303 - 323
  • [38] Antiviral prophylaxis and treatment (excluding HIV therapy)
    Waugh, SML
    Pillay, D
    Carrington, D
    Carman, WF
    JOURNAL OF CLINICAL VIROLOGY, 2002, 25 (03) : 241 - 266
  • [39] Antiviral Compounds to Address Influenza Pandemics: An Update from 2016-2022
    Romeo, Roberto
    Legnani, Laura
    Chiacchio, Maria Assunta
    Giofre, Salvatore V.
    Iannazzo, Daniela
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (18) : 2507 - 2549
  • [40] Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza
    Abraham, George M.
    Morton, Jacob B.
    Saravolatz, Louis D.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (07) : 1790 - 1794